Ductal Carcinoma in Situ: Through a Glass, Darkly
Today, ductal carcinoma in situ (DCIS) remains a growing clinical problem and a therapeutic conundrum, reflected by enormous volume of often contradictory literature devoted particularly to the mammographically detected form of this disease. Over the last 25 years, certain common findings have emerged from multiple independent studies that allow us to stratify the risk of a subsequent event related to the treatment of DCIS. Critical to our understanding of local control of DCIS is the ability to establish the margin status, size, and grade of an individual patient’s lesion and the availability of a thorough pathology protocol to permit reproducible evaluation and comparison between studies. One should be able to compare these pathological predictive factors, independently of specific treatments, and have an adequate follow-up for a disease that may not exhibit any recurrence in the initial 7–10 years. Two manuscripts published in this issue of the journal illustrate some of the common...
- 1.Dawood S, Broglio K, Gonzalez-Angulo AM, et al. Development of new cancers in patients with DCIS: The M.D. Anderson experience. Ann Surg Oncol 2007. doi: 10.1245/s10434-007-9661-8.
- 3.Meijnen P, Oldenburg H, Peterse J, et al. Clinical outcome after selective treatment for patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol 2007. doi: 10.1245/s10434-007-9659-2.